R&D channel feed – Endpoints News

R&D channel feed

Analysts are quick to pan Eli Lilly's puzzling first cut of positive clinical data for its Covid-19 antibody

5 years ago

A month after losing its lead program, Unity Biotechnology cuts 30% of staff in restructuring

5 years ago

Using AI to sequence fungi genomes for cancer treatments, Hexagon Bio nets $47M in Series A

5 years ago

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

5 years ago

Pfizer execs confidently tap their top 10 blockbusters-to-be. But what are the chances of surviving PhIII, let alone hitting these big peak sales estimates?

5 years ago

Marinus execs herald the rebirth of the one-drug biotech as a positive PhIII readout arrives for a rare disease

5 years ago

Escape Bio nabs $73M as race with well-heeled Biogen and Denali heats up

5 years ago

Here's a look at everything Merck's BD group has done in the past 12 years, illustrating why the Seattle Genetics deal stands out

5 years ago

Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates

5 years ago

Arie Belldegrun and David Chang godfather the $110M launch of a new cell therapy player. And this one is also thinking big

5 years ago

Six days after a startling trial halt, AstraZeneca gets a green light to resume dosing their Oxford Covid-19 vaccine

5 years ago

An old Vertex drug gets new life as an Alzheimer's treatment, but human studies still far off

5 years ago

Fasenra shows positive PhIII topline data for nasal polyps, tightening race with GSK's Nucala

5 years ago

Andrew Hirsch lines up a chunk of equity in his new job as C4 spells out development plans in IPO

5 years ago

Orasis Pharmaceuticals snags $30M to see its presbyopia treatment through to PhIII

5 years ago

Phase III migraine flop sends a small-cap biotech player into a deadly tailspin

5 years ago

FDA knocks back Sarepta in Duchenne gene therapy race with Pfizer, but analysts urge caution

5 years ago

With positive PhIII data, Merck sets up a blockbuster attempt to overthrow Pfizer's reigning Prevnar 13

5 years ago

Longtime biotech vet Andrew Hirsch is taking the top job at C4 — and he clearly has some big plans

5 years ago

OncoImmune pulls in $56M Series B, hoping GvHD program can prove useful for Covid-19

5 years ago

Maker of world's most expensive prescription drug flashes PhIII data for a potential fourth product

5 years ago

Dabbling in CD47, Pfizer infuses $25M into a biotech player touting positive monotherapy data

5 years ago

Analysts assess fallout after AstraZeneca halts PhIII Covid-19 vaccine dosing to probe a possible serious adverse event

5 years ago

Celltrion to begin mass producing antibody treatment before getting approval

5 years ago

First page Previous page 189 190 191192193 194 195 Next page Last page